Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

RheumMadness 2023: The Results Are In

David L. Leverenz, MD, MEd  |  Issue: September 2023  |  

All authors are part of the Rheumatology Fellowship Program at Ohio State College of Medicine, Columbus.

References

  1. Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med. 1997 Jul;337(3):141–147.
  2. Moreland LW, Margolies G, Heck LW Jr., et al. Recombinant soluble tumor necrosis factor receptor (p80) fusion protein: Toxicity and dose finding trial in refractory rheumatoid arthritis. J Rheumatol. 1996 Nov;23(11):1849–1855.

In the end, the competition came down to Cortisone vs. Etanercept for RA, with Cortisone racing away with the win.

Related Articles
    Autoantibodies in Autoimmune Myopathy

    Autoantibodies in Autoimmune Myopathy

    In recent years, scientists and clinicians have learned a great deal about autoantibodies occurring in idiopathic inflammatory myopathies (IIMs). These new discoveries have reshaped our understanding of distinct clinical pheno­types in IIMs. Scientists continue to learn more about how these auto­antibodies shape pathophysiology, diagnosis, disease monitoring, prognosis and optimum treatment. Moving forward, these autoantibodies will…

    Tasha Art; PureSolution / shutterstock.com

    RheumMadness: An Educational Tournament

    RheumMadness is an online collaborative learning experience created to educate trainees, rheumatologists and the wider medical community about recent advances and important concepts in rheumatology. The project is funded by the Rheumatology Research Foundation Clinician Scholar Educator (CSE) Award and modeled after NephMadness, an educational initiative of the American Journal of Kidney Diseases (AJKD) that…